Fennec Pharma(FENC) - 2023 Q2 - Earnings Call Transcript

Pedmarqsi was granted Pediatric Use Marketing Authorization, PUMA which includes eight years plus two years of data and market protection. In terms of our commercial strategy, we're pleased to share the results of the second quarter as we believe they underscore the growth potential of PEDMARK. We remain focused on executing the following: establishing PEDMARK as the necessary complement agent when prescribing cisplatin-based therapy for a child with localized non-metastatic solid tumor. Minimizing the barr ...